Plenary Sessions ................................................................. 1-3
Symposia .................................................................................. 4-7
Scientific Committee Sessions .............................................. 7-13
Transformative Science Groups and Subcommittees ............... 7-11
Neurology Collaborative Science Group ................................. 12
Women’s Health Inter-Network Scientific Committee .......... 13
Resource Committee Sessions .............................................. 14-21
Data Management Committee ................................................ 14
Field Representatives Working Group ................................... 15
Outreach, Recruitment, and Retention Working Group .......... 16
Pharmacy Working Group ....................................................... 17
Site Management and Clinical Care Committee ...................... 18
Site Operations Subcommittee ................................................ 19
Underrepresented Populations Committee .............................. 20
Community Sessions .............................................................. 21-27
Laboratory Sessions .............................................................. 28-44
Trainings .................................................................................. 45-54
Investigators ........................................................................... 45
Site Staff .................................................................................. 46-52
Protocol-Specific ...................................................................... 53-56
Protocol Team and Site Sessions ........................................... 57-60
PLENARY SESSION I

Monday, June 26, 2017, 4:00 p.m. – 6:00 p.m.

Chair: Daniel Kuritzkes, MD
ACTG Network Chair

Vice Chairs: Judith Currier, MD, MSc
ACTG Network Vice Chair
Ian Sanne, MBBCH, FTP (SA)
ACTG Network International Vice Chair

4:00 Welcome and Introductions
Daniel Kuritzkes, MD
Judith Currier, MD, MSc
Ian Sanne, MBBCH, FTP

4:00 NIAID: State of the Institute and Priorities in HIV/AIDS Research
Anthony Fauci, MD

4:40 State of the ACTG
Daniel Kuritzkes, MD
Judith Currier, MD, MSc
Ian Sanne, MBBCH, FTP

4:55 Recognition of ACTG Service
Daniel Kuritzkes, MD

a. 2016-2017 Minority HIV Investigator Mentoring Program
Judith Currier, MD, MSc
b. Leadership Committees
Ian Sanne, MBBCH, FTP

5:05 Presentation of 2017 ACTG Awards (4 minutes each)
Daniel Kuritzkes, MD
Judith Currier, MD, MSc
Ian Sanne, MBBCH, FTP

a. Minority HIV Investigator Mentoring Program
b. John Carey Young Investigator Award
Daniel Kuritzkes, MD
Judy Currier, MD, MSc
Cynthia Firnhaber, MD, MS
Morënike Giwa Onaiwu

Constance B. Wofsy Women’s Health Investigator Award
Lionel Hillard

5:20 A5353: Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
Babafemi Taiwo, MD, MBBS

Antiretroviral Therapy Strategies Subcommittee Scientific Committee

5:40 A5315: A Phase I/II Study of Romidepsin in HIV-Infected Adults with Suppressed Viremia on ART to Assess Safety, Tolerability, and Activation of HIV-1 Expression
Deborah McMahon, MD

HIV Reservoirs and Viral Eradication Transformative Science Group Scientific Committee
PLENARY SESSION II

*Tuesday, June 27, 2017, 8:00 a.m. – 10:00 a.m.*

**Moderator:** Ian Sanne, MBBCH, FTP (SA)
ACTG Network Vice Chair

**National Institutes of Health, Office of AIDS Research**

8:00  Future Challenges in HIV Research: Role of the Office of AIDS Research
      Maureen Goodenow, PhD

**Hepatitis Transformative Science Group**

8:20  A5327: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
      Susanna Naggie, MD

8:35  A5335s: Coinfected Subjects Treated with HCV Direct Acting Antivirals Plus Ribavirin: Intrahepatic HCV Dynamics and Pharmacology: A Substudy of A5329 (HCV GT 1 AbbVie)
      Ashwin Balagopal, MD

8:50  A5320: Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)
      David Wyles, MD

**End-organ Disease and Inflammation Transformative Science Group**

9:05  A5317: Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
      Jordan Lake, MD

9:20  A5325/A5330s: A Prospective Randomized Controlled Study to Evaluate the Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects with Incomplete CD4+ T Cell Recovery on Suppressive ART/ Evaluation of CD4+ T Cell Restoration in the Gut Mucosa of Virologically Suppressed HIV-Infected Subjects After Isotretinoin Treatment: A Substudy of A5325
      Nina Lin, MD

9:40  A5314: Effect of Reducing Inflammation with Low Dose Methotrexate on Inflammatory Markers and Endothelial Function in Treated and Suppressed HIV Infection
      Priscilla Hsue, MD
PLENARY SESSION III

Wednesday, June 28, 2017, 8:00 a.m. – 10:00 a.m.

Moderator: Judith Currier, MD, MSc
ACTG Vice Chair

ACTG Service Awards

8:00 Recognition of ACTG Service
   a. Science Committees
   b. Resource Committees
   Daniel Kuritzkes, MD
   Judith Currier, MD, MSc
   Ian Sanne, MBBCH, FTP

Tuberculosis Transformative Science Group

8:15 A5290: Rifampin-Based vs. Rifabutin-Based TB Treatment in HIV
   Constance Benson, MD

HIV Reservoirs and Viral Eradication Transformative Science Group

8:30 HIV Cure Studies in the ACTG: Where we are now, where we need to be
   Rajesh Gandhi, MD

8:50 VRC01 for HIV Reservoir Reduction (A5342)
   Sharon Riddler, MD

9:10 HIV Persistence in the Cerebrospinal Fluid (CSF)
   Serena Spudich, MD

HIV Reservoirs and Viral Eradication Transformative Science Group and Women’s Health Inter-Network Scientific Committee

9:25 Systemic Exposure to ARVs and Relationship to HIV Reservoir Measures
   Monica Gandhi, MD, MPH

Discussion

9:40 Discussion, Questions and Answers
   All Participants
SYMPOSIUM I:
END-ORGAN DISEASE AND INFLAMMATION
TRANSFORMATIVE SCIENCE GROUP (ITSG)

Tuesday, June 27, 2017, 4:00 p.m. – 6:00 p.m.

Chair: Turner Overton, MD
Alabama CRS

Vice Chair: Netanya Utay, MD
Houston AIDS Research Team CRS

Welcome and Introductions

1. Key Focus Areas of the Past (Where have we been?)
   a. Handling HAND
   b. Cardiovascular Disease and Lipids
   c. Bone Health
   d. Inflammatory Biomarkers 101
   e. Body Composition and Physical Function
   f. Inflammation International

2. The Present Focus Areas of the ITSG Agenda (Where are we now?)

3. Peering Into the Future (Where are we going?)

Turner Overton, MD
Netanya Utay, MD
David Clifford, MD
Michael Dube, MD
Michael Yin, MD
Nicholas Funderburg, PhD
Kristine Erlandson, MD
Amita Gupta, MD
SYMPOSIUM II:
TUBERCULOSIS TRANSFORMATIVE SCIENCE GROUP, NEUROLOGY COLLABORATIVE SCIENCE GROUP AND COMMUNITY SCIENTIFIC SUBCOMMITTEE

Wednesday, June 28, 2017, 10:30 a.m. – 12:30 p.m.

Tuberculosis TSG

Chair: Richard Chaisson, MD
Johns Hopkins University CRS

Co-Vice Chairs: Gavin Churchyard, MBBCh, MMed, FCP, PhD
The Aurum Institute for Health Research
Diane Havlir, MD
San Francisco Bay CTU

Neurology CSG

Chair: Scott Letendre, MD
University of California San Diego AntiViral Research Center CRS

Vice Chair: Ronald Ellis, MD, PhD
University of California San Diego AntiViral Research Center CRS

Community Scientific Subcommittee and Global Community Advisory Board

Co-Chairs: Danielle Campbell, MPH
University of California Los Angeles CARE Center CRS
Morénike Giwa Onaiwu, MA
Houston AIDS Research Team CRS

Tuberculosis Transformative Science Group

10:30  TB-HIV Drug-Drug Interactions (Rifapentine-Dolutegravir/TAF)  Charles Flexner, MD
10:50  Advances in MDR and XDR TB Treatment  Francesca Conradie, MBBCH
11:10  Landscape of TB Diagnostics  Susan Dorman, MD
11:25  TB Morbidity and Mortality in People with Advanced HIV  Kevin Cain, MD

Neurology Collaborative Science Group

11:40  Imaging of the Brain: Challenges and Opportunities  Beau Ances, MD, PhD, MSc
Ann Ragin, PhD

Global Community Advisory Board and Community Scientific Subcommittee

12:10  Community Update Roots and Wings: Drawing From Our Past and Crafting Our Future  Danielle Campbell
Morénike Giwa Onaiwu, MA
SYMPOSIUM III:  
HEPATITIS TRANSFORMATIVE SCIENCE GROUP (TSG) AND  
HIV RESERVOIRS AND VIRAL ERADICATION TRANSFORMATIVE SCIENCE GROUP (CURE TSG)  

Thursday, June 29, 2017, 8:45 a.m. – 11:15 a.m.

Hepatitis TSG  

Chair: Mark Sulkowski, MD  
Johns Hopkins University CRS  

Vice Chair: Susanna Naggie, MD  
Duke University Medical Center CRS  

CURE TSG  

Chair: Rajesh Gandhi, MD  
Massachusetts General Hospital CRS  

Vice Chair: Pablo Tebas, MD  
Philadelphia Therapeutics and Prevention CTU  

Hepatitis Transformative Science Group  

8:45 The Role of the Kupffer Cell in HIV Infection  
Ashwin Balagopal, MD  

9:10 HIV, Metabolomics and the Liver  
Susanna Naggie, MD  

HIV Reservoirs and Viral Eradication Transformative Science Group  

9:30 Update on Ad26/MVA Vaccine Studies and Potential Applications to HIV Cure Research  
Merlin Robb, MD  

10:05 A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination for HIV Infection  
Jeffrey Jacobson, MD  
Alan Landay, PhD  

10:40 Targeting HIV Where It Hurts  
Tomas Hanke, PhD
ANTIRETROVIRAL THERAPY STRATEGIES SUBCOMMITTEE (ARTS SC)
THINK TANK

Tuesday, June 27, 2017, 1:30 p.m. – 3:30 p.m.

Chair: Raphael Landovitz, MD, MSc
University of California, Los Angeles CARE Center CRS

Vice Chair: Ighovwerha Ofotokun, MD, MSc
The Ponce de Leon Center CRS

1. Welcome and Introductions ARTS SC Leadership

2. The Current “State of the Art” ART – What are our Opportunities? An Interactive Discussion Roy Gulick, MD, MPH

3. Modelling Collaborations to Inform Trial Design and Impact Kenneth Freedberg, MD, MSc
   a. PR 731: Simplified Treatment with a Dolutegravir-Based Antiretroviral Regimen (STAR) Thomas Campbell, MD, PhD
   b. A5359: Long Acting ARVs in Non-Adherent Participants Jose Castillo-Mancilla MD

4. Working Group Updates
   a. Monoclonal Antibodies Working Group Pablo Tebas, MD
   b. Hard to Reach Populations Working Group Raphael Landovitz, MD
Welcome and Introductions

1. The Microbiome and Health Implications
   a. The IDO Metabolic Pathway in the Setting of HIV Dysbiosis
      Richard Dunham, PhD
   b. Changes in the Microbiome in Acute HIV
      Irini Sereti, MD

2. NASH/NAFLD
   a. Cenicriviroc for NASH in the Setting of HIV
      Eric Lefebvre, MD
   b. Update on NASH/NAFLD Proposals
      • PR 730, Version 3: “Potential Treatment Strategies for NASH, A Metabolic Syndrome with Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk”
      Jordan Lake, MD
      • PR 736, Version 2: “Pharmacokinetic Study of Contemporary Antiretroviral Agents Before and During Combined Administration with Obeticholic Acid in HIV-1 infected Participants with Suspected NASH”
      Mark Sulkowski, MD

3. Statistical and Data Analysis Center Orientation
   a. Introduction of the ITSG Statistical Section
   b. The Role of the Protocol Statistician
   Carlee Moser, PhD
HEPATITIS TRANSFORMATIVE SCIENCE GROUP
THINK TANK

Tuesday, June 27, 2017, 10:30 a.m. – 12:30 p.m.

Chair:    Mark Sulkowski, MD
          Johns Hopkins University CRS

Vice Chair:  Susanna Naggie, MD
             Duke University Medical Center CRS

1. EASL 2017: NASH and Hepatitis B Virus (HBV) Recap    Mark Sulkowski, MD

2. Overview of A5368: Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy    Debika Bhattacharya, MD, MSc

3. Translational Approaches to HBV Cure    Michael Sofia, PhD

4. Perspectives on Immune Checkpoint Inhibition and Hepatocellular Carcinoma    Tim Greten, MD
HIV RESERVOIRS AND VIRAL ERADICATION
TRANSFORMATIVE SCIENCE GROUP (Cure TSG)
THINK TANK

Tuesday, June 27, 2017, 10:30 a.m. – 12:30 p.m.

Chair: Rajesh Gandhi, MD
Massachusetts General Hospital CRS

Vice Chair: Pablo Tebas, MD
Philadelphia Therapeutics and Prevention CTU

10:30 Introduction to Think Tank Goals
Rajesh Gandhi, MD
Pablo Tebas, MD

Guest Speaker
10:35 Immune Checkpoint Inhibitors
Jarushka Naidoo, MBBCh

Implications of Ongoing Trials
11:15 Latency Reversing Agents: Update on Current and Future Agents
Mathias Lichterfeld, MD, PhD

11:35 A5354 (Early ART in Acute HIV): Update on Current Status and Open Discussion of Potential Interventional Studies
Jintanat Ananworanich, MD, PhD
Eric Daar, MD
Trevor Crowell, MD, PhD
Javier Lama, MD, MPH

Future Directions
11:55 Concept Proposal, “A Randomized Trial of Therapeutic Vaccination with Conserved HIV-1 Immunogens in Early-treated HIV-infected Adults”
Sharon Riddler, MD

12:05 Open Discussion
All
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00</td>
<td>Welcome and Update</td>
<td>Richard Chaisson, MD</td>
</tr>
<tr>
<td>4:05</td>
<td>Adherence Monitoring for TB Trials</td>
<td>Jessica Haberer, MD, MS</td>
</tr>
<tr>
<td>4:30</td>
<td>Risk-benefit Analysis for TB Clinical Trials</td>
<td>Sachiko Miyahara, PhD; Ritesh Ramchandani, PhD</td>
</tr>
<tr>
<td>4:55</td>
<td>LTBI Model in Non-human Primate (NHP)</td>
<td>Deepak Kaushal, PhD</td>
</tr>
<tr>
<td>5:15</td>
<td>Knowledge, Attitudes and Practices about Multidrug-Resistant Tuberculosis (MDR TB) and Preventive Therapy among Household Contacts of MDR TB Index Cases (A5300/I2003)</td>
<td>Vidya Mave, MD, MPH</td>
</tr>
<tr>
<td>5:25</td>
<td>Update from the NIH Meeting on TB Meningitis</td>
<td>Kelly Dooley, MD, PhD</td>
</tr>
<tr>
<td>5:40</td>
<td>Further Review of PR 742, “A Phase III, Randomized Controlled Trial for the Treatment of Isoniazid Mono- and Poly-Resistant Tuberculosis (The IMPaRT Trial)”</td>
<td>Jennifer Furin, PhD; Serena Koenig, MD</td>
</tr>
</tbody>
</table>
## NEUROLOGY COLLABORATIVE SCIENCE GROUP (NEURO CSG) SESSION AND THINK TANK

*Tuesday, June 27, 2017, 2:30 p.m. – 4:30 p.m.*

**Chair:** Scott Letendre, MD  
University of California, San Diego AntiViral Research Center CRS

**Vice Chair:** Ronald Ellis, MD, PhD  
University of California, San Diego AntiViral Research Center CRS

### Part I Business Session

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:30</td>
<td>Welcome and Introductions</td>
<td>Neuro CSG Chairs</td>
</tr>
<tr>
<td>2:45</td>
<td>Review of 2016-2017 Accomplishments</td>
<td>Scott Letendre, MD</td>
</tr>
<tr>
<td>3:10</td>
<td>Discussion: The ACTG Process for New Research</td>
<td>All Members</td>
</tr>
</tbody>
</table>

### Part II Think Tank

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:20</td>
<td>Mitochondria and the Central Nervous System (CNS)</td>
<td>Robert Kalayjian, MD</td>
</tr>
<tr>
<td>3:40</td>
<td>The Frailty Phenotype and the CNS</td>
<td>Kristine Erlandson, MD</td>
</tr>
<tr>
<td>4:10</td>
<td>OAR Priorities for Neuropsychiatric Research</td>
<td>Gina Brown, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stacy Carrington-Lawrence, PhD</td>
</tr>
</tbody>
</table>
WOMEN’S HEALTH INTER-NETWORK SCIENTIFIC COMMITTEE (WHISC) THINK TANK

Wednesday, June 28, 2017, 4:00 p.m. – 6:00 p.m.

Chair: Cynthia Firnhaber, MD, MS, DTM&H
University of Colorado Medical Center

Vice Chair: Elizabeth Connick, MD
University of Arizona CRS

4:00 Welcome and Introductions
Cynthia Firnhaber, MD
Elizabeth Connick, MD

End-Organ Disease/Inflammation Transformative Science Group and WHISC Joint Session

4:05 A5322: The HIV Infection, Aging, and Immune Function Long-Term Observational Study (HAILO)
Kristine Erlandson, MD
Frank Palella, MD
Katherine Tassiopoulos, ScD

4:30 Discussion
All

4:40 NWCS 407: Sex Differences in Weight Gain Following the Initiation of ART
Sara Bares, MD

4:50 Discussion
All

A5282: HPV Test-and-Treat Study
5:00 A5282 Arm C
Rosie Mngqibisa, MBChB, MPH

Women’s Outreach Workers (WOW) Project/REPRIEVE (A5332)

5:15 Overview
Susan Cohn, MD, MPH

5:17 History of WOW Initiative
Liz Barr, PhD

5:25 WOW from Emory
Anna Benbrook, MS

5:30 WOW from Rutgers
Baljinder Singh, MS

5:35 Recruitment of Women and Under-represented Group
Carlos del Rio, MD

5:50 Update: REPRIEVE (A5332) Women’s Objectives
Sara Dolan Looby, PhD
DATA MANAGEMENT COMMITTEE
BUSINESS SESSION

Wednesday, June 28, 2017, 3:00 p.m. – 4:00 p.m.

Co-Chairs: Robert Murphy, MD
Chicago CTU

Doug Kitch, MS
ACTG Statistical and Data Analysis Center

Minhee Kang, PhD
ACTG Statistical and Data Analysis Center

1. Welcome and Introductions Robert Murphy, MD
2. Demonstration of E-Screens Kristine Coughlin, BA
3. Medidata Rave Update Kristine Coughlin, BA
4. Generic CRF's Update Kristine Coughlin, BA
5. Open Discussion All Members
FIELD REPRESENTATIVES WORKING GROUP SESSION

Monday, June 26, 2017, 3:00 p.m. – 4:00 p.m.

Leader: Kathy Watson, RN
Ohio State University CRS

Co-Leader: Susan Pedersen, RN, BSN
Chapel Hill CRS

1. Introductions
Kathy Watson, RN
Susan Pedersen, RN, BSN

2. Field Representatives Recognition
Kathy Watson, RN
Susan Pedersen, RN, BSN

3. The Clinical Trials Specialist and the Field Representative Conversation and Collaboration
Kathy Watson, RN
Susan Pedersen, RN, BSN
Evelyn Hogg, BA
Lara Hosey, MA, CCRP
Jennifer Tiu, BS, MPH
Vicki Stocker, RN, MS
# OUTREACH, RECRUITMENT, AND RETENTION (ORR) WORKING GROUP BUSINESS SESSION

**Tuesday, June 27, 2017, 12:30 p.m. – 1:30 p.m.**

**Chair:** Robert Bucklew Jr, JD  
Case Clinical Research Site

**Vice Chair:** Jan Fritsche MS, APRN, PMHNP, BC  
Rush University CRS

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
</table>
| 12:30 | Welcome, Introductions and Updates                                     | Robert Bucklew, Jr, JD  
Jan Fritsche, MS, APRN, PMHNP, BC                  |
| 12:35 | ORR Website                                                           | Patricia Kittelson BS, MLS                         |
| 12:40 | ACTG Day of Appreciation for Participants/Volunteers – December 2, 2017 | Robert Bucklew, Jr, JD  
Jan Fritsche, MS, APRN, PMHNP, BC                  |
| 12:45 | ORR CRS Survey Project                                                | Robert Bucklew Jr, JD                             |
| 1:00  | Recruitment without Resources: Sharing Low-Cost (No-Cost) Methods of Community Education/Outreach and Participant Recruitment and Retention | ORR Working Group Members/Friends                  |
PHARMACY WORKING GROUP (PWG) BUSINESS SESSION

*Tuesday, June 27, 2017, 3:00 p.m. – 4:00 p.m.*

**Leader:** Grady Douglas, RPh
Houston AIDS Research Team CRS

**Co-Leader:** Marlize Smuts, MPharm
Family Clinical Research Unit CRS

1. Introductions
   Grady Douglas, RPh

2. HPTN 083, “A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men” Requirements and Updates
   Thiago Torres, RPh, PhD

3. Review of PWG Role in Protocol Development and Implementation Steering Committee and the Community
   All Members

4. Future Projects
   All Attendees

5. Open Discussion
   All Attendees
SITE MANAGEMENT AND CLINICAL CARE COMMITTEE (SMCCC)
BUSINESS SESSION

*Wednesday, June 28, 2017, 10:30 a.m. – 11:30 a.m.*

**Chair:** Ilene Wiggins, RN  
Johns Hopkins University CRS

**Co-Vice Chairs:** Suzanne Fiorillo, MSPH  
University of Colorado Hospital CRS  
Smita Nimkar, MSc  
Byramjee Jeejeebhoy Government Medical College CRS

1. Welcome and Introductions  
   Ilene Wiggins, RN
2. Subcommittee Updates  
   Subcommittee Leaderships
3. Source Documents Special Committee Update  
   Ilene Wiggins, RN
4. Brainstorm New Ideas for the Upcoming Year  
   All Participants
SITE OPERATIONS SUBCOMMITTEE SESSION

Tuesday, June 27, 2017, 3:30 p.m. – 4:30 p.m.

Chair: Jane Baum, RN
Case CTU

Co-Vice Chairs: Vuyo Jezile, BBSc
University of the Witwatersrand Helen Joseph CRS

Shirley Ventresca
Ohio State University CRS

1. Welcome and Introductions Jane Baum, RN

2. Ongoing Projects
   a. Reviewing and Updating the Checklists for Orientation: Research Nurse, Site Study Coordinator, Data Manager Jane Baum, RN
   b. HANC and Financial Disclosures Vuyo Jezile, BBSc
   c. CRF Destruction and Notification to Sites when New Studies are Added Shirley Ventresca
   d. Update on Source Documents Project All Participants

3. Mentoring Program Vuyo Jezile, BBSc
   James Gavel, BS

4. Suggestions for Topics for Study Coordinators and Data and Quality Managers Calls All Participants
UNDERREPRESENTED POPULATIONS COMMITTEE
BUSINESS SESSION

Wednesday, June 28, 2017, 12:30 p.m. – 1:30 p.m.

Chair: Jose Castillo-Mancilla, MD
University of Colorado Hospital CRS

Vice Chair: Carlos del Rio, MD
The Ponce de Leon Center CRS

1. Welcome and Introductions
   Jose Castillo-Mancilla, MD

2. 2017-2018 ACTG Minority HIV Investigator Mentoring Program (MHIMP) Awardees Introductions
   Jose Castillo-Mancilla, MD

3. 2016-2017 MHIMP Presentations
   Jose Gutierrez Contreras, MD, MPH
   Hansel Arroyo, MD

4. Post-Women’s Outreach Worker (WOW) Presentation Strategies
   Susan Cohn, MD, MPH
   Carlos del Rio, MD
   Shobha Swaminathan, MD

5. Discussion/Closing
   All Members
COMMUNITY SCIENTIFIC SUBCOMMITTEE (CSS) SESSION I

*Tuesday, June 27, 2017, 12:00 p.m.– 2:00 p.m.*

**CSS Co-Chairs:** Danielle Campbell
University of California, Los Angeles CARE Center CRS

Royce Hardin
Chapel Hill CRS

1. **Inflammatory Markers** – What do they do, where do they come from, what do they mean?
   
   Michael M. Lederman M.D

2. **CSS Members Training**
   
   Danielle Campbell
   Royce Hardin
COMMUNITY SCIENTIFIC SUBCOMMITTEE (CSS) II

*Wednesday, June 28, 2017, 2:00 p.m. – 4:00 p.m.*

**Co-Chairs:** Danielle Campbell  
University of California, Los Angeles CARE Center CRS  
Royce Hardin  
Chapel Hill CRS

1. **CSS Business Session**  
   Danielle Campbell  
   Royce Hardin

2. **A5345 (HIV Rebound & Control Biomarkers)**  
   Jonathan Li, MD  
   Bernard Macatangay, MD
GLOBAL COMMUNITY ADVISORY BOARD (GCAB) SESSION I

Sunday, June 25, 2017, 9:00 a.m. – 12:00 p.m.

GCAB Co-Chairs: Morenike Giwa Onaiwu
Houston AIDS Research Team CRS
Lionel Hillard
Trinity Health and Wellness Center CRS

CSS Co-Chairs: Danielle Campbell, MPH
University of California, Los Angeles CARE Center CRS
Royce Hardin
Chapel Hill CRS

1. Welcome and Introductions
   Morenike Giwa Onaiwu
   Lionel Hillard

2. ACTG Oral History: Where we’ve been and where we might go
   Liz Barr, PhD

3. CAB Presentations: Kampala, Kericho
   Ronald Ssenyonga, Moses Nsubuga
   Flavia Miiro
   Janat Kayondo
   John Rotich
   Nickson Chepkwony

4. Treatment Shortening Tuberculosis Research
   Kelly Dooley MD, PhD
GLOBAL COMMUNITY ADVISORY BOARD (GCAB) SESSION II

*Sunday, June 25, 2017, 1:00 pm – 6:00 p.m.*

**GCAB Co-Chairs:** Morenike Giwa Onaiwu  
Houston AIDS Research Team CRS

Lionel Hillard  
Trinity Health and Wellness Center CRS

**CSS Co-Chairs:** Danielle Campbell, MPH  
University of California, Los Angeles CARE Center CRS

Royce Hardin  
Chapel Hill CRS

1. Community Agenda Discussion  
   Larry N. Lyle DO, MS

2. Community Interactive  
   Morenike Giwa Onaiwu,  
   Lionel Hillard

3. Cross Network Transgender Working Group  
   Rona Siskind MHS

4. CAB Presentation  
   Philadelphia CAB/SATVI CAB Activities  
   Jay Johnson  
   Belinda Ameterra

5. Community-Staff Interactive: Intersectionality  
   Jonatan E. Gioia MD  
   Melissa Murry, BA
GLOBAL COMMUNITY ADVISORY BOARD (GCAB) SESSION III

Monday, June 26, 2017, 8:00 a.m. – 12:00 p.m.

GCAB Co-Chairs: Morenike Giwa Onaiwu
Houston AIDS Research Team CRS

Lionel Hillard
Trinity Health and Wellness Center CRS

CSS Co-Chairs: Danielle Campbell, MPH
University of California, Los Angeles CARE Center CRS

Royce Hardin
Chapel Hill CRS

1. Understanding the Human Microbiome in HIV Disease Alan Landay PhD
2. Education, Technology, Social Media, & Connecting with Our Communities: An Interactive Panel ORR, GCAB and CSS Members
3. Possible Drug/Drug Interactions of HIV Medications with Other Classes of Drugs Grady Doublass RPh
4. Turning the Corner on the AIDS Pandemic: Refining the Science-Driven HIV Research Enterprise Carl Dieffenbach PhD
GLOBAL COMMUNITY ADVISORY BOARD (GCAB) SESSION IV

Monday, June 26, 2017, 1:15 p.m. – 3:30 p.m.

GCAB Co-Chairs: Morenike Giwa Onaiwu
Houston AIDS Research Team CRS

Lionel Hillard
Trinity Health and Wellness Center CRS

CSS Co-Chairs: Danielle Campbell, MPH
University of California, Los Angeles CARE Center CRS

Royce Hardin
Chapel Hill CRS

1. Sex Differences in HIV Cure Research  Sara Gianella MD
   Eileen Scully MD, PhD

2. NASH  Mark S. Sulkowski MD
GLOBAL COMMUNITY ADVISORY BOARD (GCAB) SESSION V

*Thursday, June 29, 2017, 12:00 p.m. – 3:00 p.m.*

**GCAB Co-Chairs:**
- Morenike Giwa Onaiwu
  Houston AIDS Research Team CRS
- Lionel Hillard
  Trinity Health and Wellness Center CRS

**CSS Co-Chairs:**
- Danielle Campbell, MPH
  University of California, Los Angeles CARE Center CRS
- Royce Hardin
  Chapel Hill CRS

1. **Incidental Findings**
   - Betto Ortiz, MS, PMP, CIPM
   - Linda A. Ehler RN, MN

2. **Reports**
   - CSS and GCAB Representatives

3. **Awards, Closing Thoughts**
   - Morenike Giwa Onaiwu
   - Lionel Hillard
   - Allegra Cermak
A5349/TBTC STUDY 31  
(RIFAPENTINE-CONTAINING TUBERCULOSIS TREATMENT SHORTENING REGIMENS)  
LABORATORY FOCUSED TRAINING  

*Tuesday, June 27, 2017, 7:00 a.m. – 8:00 a.m.*

**Chair:** Anne Purfield, PhD  
U.S. Centers for Disease Control and Prevention

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>Introductions and Welcome</td>
<td>Morgan Gapara, MPH</td>
</tr>
</tbody>
</table>
| 7:02  | A5349 Laboratory Testing Review: Basics and Highlights | Anne Purfield, PhD  
Nicole Brown, PhD |
| 7:10  | Completing the Microbiology (MB) Form      | Anne Purfield, PhD  
Nicole Brown, PhD |
| 7:30  | Questions and Answers/Closing              |                                   |
ELECTRONIC LABORATORY TESTING PLANS (ePAL)  
MIS OVERVIEW SESSION

Monday, June 26, 2017 12:30 p.m. – 1:30 p.m.

Facilitator: Kim Banks, MS, MBA, MT (AMT)  
ACTG Network Coordinating Center

12:30  Introductions and Welcome  
       Kim Banks, MS, MBA, MT (AMT)  
       Jenny Nguyen, BS

12:35  Electronic Laboratory Testing Plans (ePAL) Presentation and Demonstration  
       Kim Banks, MS, MBA, MT (AMT)  
       Jenny Nguyen, BS

1:15  Questions and Answers/Closing
FUTURE DIRECTIONS AND PROGRESS OF THE ACTG NETWORK LABORATORY CENTER

Sunday, June 25, 2017, 8:00 a.m. – 10:00 a.m.

Chair: Robert Coombs, MD, PhD
ACTG Network Laboratory Center Principal Investigator
University of Washington AIDS Clinical Trials Unit CRS

8:00 Introductions and Welcome
Robert Coombs, MD, PhD

8:05 Laboratory Center Leadership Update
Robert Coombs, MD, PhD

8:50 QuantiFERON Gold Plus Validation Update
Peter Meewes

9:20 Evaluation of Xpert HIV-1 VL Assay and Non-inferiority of the Xpert Ultra Compared to the Xpert MRB/RIF for Initial Diagnosis of Pulmonary Tuberculosis and MDR-TB
Lesley Scott, PhD

9:50 Introduction of New TB QA Program
Daniella Livnat, BS

9:55 Questions and Answers/Closing
IMMUNOLOGY SPECIALTY LABORATORY (ISL)
BREAKOUT SESSION

Wednesday, June 28, 2017, 11:15 a.m. – 1:15 p.m.

Chair: Michael Lederman, MD
Case Western Reserve University School of Medicine
Immunology Specialty Laboratory

11:15 Introductions and Welcome
Michael Lederman, MD

11:20 Case ISL: A Tale of 2 CDs
Michael Lederman, MD

11:45 Rush ISL: Immunometabolism and HIV
Alan Landay, PhD

12:05 Pittsburgh ISL: Evaluating Levels of pro- and anti-
Inflammatory Soluble Mediators in Throat Washings of
Participants in A5254 "HIV-Related Oral Mucosal Disease &
Use of Saliva in Measuring HIV Viral Load"
Bernard Macatangay, MD

12:30 SUN-IRG: Phenotype and non-Humoral Functions of B Cells
during M.tb Infection and Disease
Andre Loxton, PhD

12:55 Luminex-EIA Biomarker Project Next Steps
All Members

1:10 Questions and Answers/Closing
**IMPROVING QUALITY ASSURANCE PRACTICES IN THE LABORATORY**

**Sunday, June 25, 2017 11:30 a.m. – 1:30 p.m.**

**Facilitator:** Kim Banks, MS, MBA, MT (AMT)
ACTG Network Coordinating Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td>Blood Specimens Processing Quality Management</td>
<td>Joan Dragavon, MLM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sarah Keinonen, BS</td>
</tr>
<tr>
<td>12:10</td>
<td>Molecular Virology and TB Testing Laboratory</td>
<td>Peter Meewes</td>
</tr>
<tr>
<td></td>
<td>Contamination Panel Discussion</td>
<td>Peggy Coulter, BS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jeanette Coffin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cheryl Jennings, BS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Raquel Viana, PhD</td>
</tr>
<tr>
<td>1:10</td>
<td>Improvement of Quality Assurance Management: AMPATH Perspective Panel</td>
<td>Ibrahim Daud, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Millicent Orido, BS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Michele Imbach, MS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anita Gillis, MPH</td>
</tr>
</tbody>
</table>
INTERNATIONAL AIR TRANSPORT ASSOCIATION (IATA) SHIPPING TRAINING

Sunday, June 25, 2017 1:30 p.m. – 5:00 p.m.

Chair: David Shugarts, MA
University of Colorado Hospital CRS

1. ACTG and BRI Shipping Regulations and Shipping  David Shugarts, MA
2. Introduction to IACO/IATA, U.S. Department of Transportation Dangerous Goods Shipping  David Shugarts, MA
3. Category A Infectious Substance Shipping  David Shugarts, MA
4. Category B Infectious Substances Shipping  David Shugarts, MA
5. Procedure for Filling Cryovials for REPRIEVE (A5332) Studies  David Shugarts, MA
6. Liquid Nitrogen Dry Shipper Demonstration  David Shugarts, MA
7. Repository Instructions for Pass Through Shipments  David Shugarts, MA
8. Certification Test  David Shugarts, MA
LABORATORY SCIENCE GROUP (LSG)  
DROP-IN ROOM  

_Sunday, June 25, 2017, 3:00 p.m. – 4:30 p.m._  
_and_  
_Monday, June 26, 2017, 1:30 p.m. – 2:30 p.m._  

_Facilitators:_ Members of the ACTG LSG

1. Meet with the ACTG Network Coordinating Center LSG  
2. Hands-on Demonstrations Accessing and Updating the ePAL in MIS  
3. Review and Provide Guidance to ACTG Laboratories on Meeting DAIDS and ACTG Laboratory Requirements  
4. Answer Laboratory Readiness Questions  
5. ACTG Laboratory Approval Questions  
6. Review Upcoming Protocol Testing Requirements
LABORATORY TECHNOLOGIST COMMITTEE (LTC)
DROP-IN ROOM

Wednesday, June 28, 2017, 7:00 a.m. – 8:00 a.m.

Co-Chairs: Christopher Lane, AAS
University of Rochester Adult HIV Therapeutic Strategies Network CRS

David Shugarts, MA
University of Colorado Hospital CRS

Co-Vice Chairs: Francoise Gigué
Harvard University Virology Specialty Laboratory

Sikhulile Moyo, MS, MPH, PhD
Gaborone CRS

1. Questions and Answers Regarding the LTC

   LTC Members
LABORATORY TECHNOLOGIST COMMITTEE
OPEN TRAINING SESSION

Sunday, June 25, 2017 5:00 p.m. – 6:00 p.m.

Co-Chairs: David Shugarts, MA
University of Colorado Hospital CRS
Christopher Lane, AAS
University of Rochester Adult HIV Therapeutic Strategies Network CRS

Co-Vice Chairs: Francoise Giguel
Harvard University Virology Specialty Laboratory
Sikhulile Moyo, PhD, MS, MPH
Gaborone CRS

5:00 Introductions and Welcome
David Shugarts, MA
Christopher Lane, AAS

5:02 Validation and Verification of Spreadsheets to Comply with FDA and CFR11
Joan Dragavon, MLM

5:20 Statistical Presentation- Analyzing Data That Has Below Assay Limit
Ronald Bosch, PhD

5:35 Cold Change and Laboratory Clinic Interaction
Francoise Giguel
Sikhulile Moyo, PhD, MS, MPH

5:55 Questions and Answers/Closing
LDMS DROP-IN ROOM

Monday, June 26, 2017, 9:00 a.m. – 5:00 p.m.
and
Tuesday, June 27, 2017, 9:00 a.m. – 5:00 p.m.

Chair: Andrew Lohrum, MLIS
ACTG Data Management Center
Frontier Science

1. Walk-In LDMS Questions
2. Individual Help Sessions
3. Demonstrate and Instruct on All Functions of the LDMS for Windows or Web (Accessioning, Storage, Shipping and Supported Assays, Windows)
LDMS/LABORATORY TECHNOLOGIST COMMITTEE INTERACTIVE

Monday, June 26, 2017 2:00 p.m. – 4:00 p.m.

Facilitator: Morgan Gapara, MPH
ACTG Network Coordinating Center

2:00   Introductions and Welcome   Morgan Gapara, MPH
2:02   Brief Discussion on Recent Updates to Windows LDMS Version 12.X   Howard Gutzman, BS
2:10   Everything to Know About Web LDMS!   Howard Gutzman, BS
2:45   Status of Migrating Labs to Web LDMS   Howard Gutzman, BS
3:00   Live Demo of Web LDMS and LDMS Website   Howard Gutzman, BS
3:30   Overview of DMC Tools on FSTRF Portal   Howard Gutzman, BS
3:45   Question and Answers/Closing
PATIENT SAFETY MONITORING IN INTERNATIONAL LABORATORIES (PSMILE) 
DROP-IN ROOM

Sunday, June 25, 2017, 11:00 a.m. – 3:00 p.m.

Chair: Anne Leach, MT (ASCP) 
            pSMILE

1. Answer Clinical and TB Laboratory QA/QC Questions Including QuantiFERON-TB Gold Plus (QFT-Plus) Validation Update
2. Troubleshooting (Action Plans, Investigation Reports, Validation…)
3. Assist with EQA Submission Questions and Challenges Including 3rd and 4th Generation HIV Tests
4. Demonstrate and Assist with Accessing the pSMILE Website
5. Demonstrate and Assist with Accessing the MTS Competency and Training Website
6. Demonstrate the pSMILE Website Resources Section
PHARMACOLOGY SPECIALTY LABORATORY (PSL)/
CLINICAL PHARMACOLOGY ADVISORY GROUP (CPAG)
BREAKOUT SESSION

Wednesday, June 28, 2017 - 10:00 a.m. – 12:00 p.m.

Chair: Gene Morse, PharmD
State University of New York at Buffalo PSL
University of Rochester Adult HIV Therapeutic Strategies Network CRS

10:00 Introductions and Welcome
Gene D. Morse, PharmD

10:05 Protocol Updates
CPAG Members

10:40 University of Alabama, Birmingham PSL Update
Chantelle Bennetto Hood, PhD

10:50 University of California, San Francisco PSL Update
Can we spell out the lab names?
Anastasia Makarova, PhD

11:00 UCSF Hair Analytical Laboratory
Monica Gandhi, MD, MPH

11:10 University of Nebraska, Medical Center PSL Update
Anthony Podany, PharmD
Kim Scarsi, PharmD, MS, BCPS

11:20 SUNY at Buffalo PSL
Charles Venuto, PharmD
Qing Ma, PhD

11:30 University of Zimbabwe International PSL Update
Charles Maponga, PharmD

11:40 University of Capetown International PSL Update
Jennifer Norman, MSc

11:50 CPQA Update
Robin DiFrancesco, MT, (ASCP), MBA
# SPECIALTY LABORATORY DIRECTORS BUSINESS SESSION

**Monday, June 26, 2017 10:00 a.m. – 12:00 p.m.**

**Chair:** Robert Coombs, MD, PhD  
ACTG Laboratory Center Principal Investigator  
University of Washington AIDS Clinical Trials Unit CRS

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Introductions and Welcome</td>
<td>Robert Coombs, MD, PhD</td>
</tr>
<tr>
<td>10:05</td>
<td>Award for Cheryl Jennings</td>
<td>Robert Coombs, MD, PhD</td>
</tr>
<tr>
<td>10:15</td>
<td>Pharmacology Biomarker Update</td>
<td>Robin DiFrancesco, MT (ASCP), MBA</td>
</tr>
<tr>
<td>10:35</td>
<td>Genomics 101</td>
<td>David Haas, MD</td>
</tr>
<tr>
<td>11:10</td>
<td>Potential Crossover Studies for HIV Reservoirs and Viral Eradication Transformative Science Group</td>
<td>John Mellors, MD</td>
</tr>
<tr>
<td>11:45</td>
<td>Questions and Answers/Closing</td>
<td></td>
</tr>
</tbody>
</table>
Co-Chairs: Nicole Brown, PhD
U.S. Centers for Disease Control and Prevention
Anne Purfield, PhD
U.S. Centers for Disease Control and Prevention

4:00 Introductions and Welcome
Anne Purfield, PhD

4:05 MGIT Testing Algorithm
Anne Purfield, PhD
Nicole Brown, PhD

5:20 Questions and Answers/Closing
TUBERCULOSIS (TB) QUALITY ASSURANCE LABORATORY DISCUSSION

Sunday, June 25, 2017, 10:00 a.m. – 11:30 a.m.

Facilitator: Morgan Gapara, MPH
ACTG Network Coordinating Center

10:00 Introductions and Welcome
Morgan Gapara, MPH

10:02 MRIGlobal Overview
Jeanette Coffin

10:20 TB Manual Presentation (Harmonization Guides)
Anne-Marie Demers, MD
Kathy Eisenach, PhD

10:45 Comparing Genotypic and Phenotypic Drug Susceptibility Testing (DST)
Carole Wallis, PhD

11:00 A5349 (TBTC S31), Changes in Quality Assurance and TB Contamination
Anne Purfield, PhD

11:20 Questions and Answers/Closing
VIROLOGY SPECIALTY LABORATORIES (VSL),
GENOTYPING AND STATISTICAL AND DATA ANALYSIS CENTER (SDAC)
BREAKOUT SESSION

*Wednesday, June 28, 2017, 10:00 a.m. – 12:00 p.m.*

**Chair:** John Mellors, MD  
University of Pittsburgh VSL

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Introductions and Welcome</td>
<td>John Mellors, MD</td>
</tr>
<tr>
<td>10:02</td>
<td>New Scientific Updates: Vanderbilt DNA Resources Core</td>
<td>David Haas, MD</td>
</tr>
<tr>
<td>10:15</td>
<td>New Scientific Updates: SDAC</td>
<td>Ronald Bosch, PhD</td>
</tr>
<tr>
<td>10:30</td>
<td>International Genotyping Laboratories Update</td>
<td>Carole Wallis, MSc, MED, PhD</td>
</tr>
<tr>
<td>10:45</td>
<td>New Scientific Updates: University of Pittsburgh VSL</td>
<td>John Mellors, MD</td>
</tr>
<tr>
<td>11:05</td>
<td>New Scientific Updates: University of Washington VSL</td>
<td>Robert Coombs, MD, PhD</td>
</tr>
<tr>
<td>11:25</td>
<td>New Scientific Updates: Harvard University VSL</td>
<td>Daniel Kuritzkes, MD</td>
</tr>
<tr>
<td>11:45</td>
<td>VQA Update on Virology Specialty Assays EQA Efforts</td>
<td>Cheryl Jennings, BS</td>
</tr>
<tr>
<td>12:00</td>
<td>Questions and Answers/Closing</td>
<td></td>
</tr>
</tbody>
</table>
INTRODUCTION TO THE ACTG:
A WORKSHOP FOR NEW INVESTIGATORS

Monday, June 26, 2017, 10:30 a.m. – 12:00 p.m.

Chair: Judith S. Currier, MD, MSc
ACTG Network Vice Chair

1. Introduction and ACTG Structure
   Judith Currier, MD, MSc

2. Scientific Committee Directions:
   Opportunities for New Investigators
   a. Antiretroviral Therapy Strategies Subcommittees
   b. HIV Reservoir and Viral Eradication
      Transformative Science Group (TSG)
   c. Hepatitis TSG
   d. End-Organ and Inflammation TSG
   e. Tuberculosis TSG
   TBA

3. Introduction to the Statistical and Data
   Analysis Center
   Summer Zheng, PhD

4. Protocol Team Involvement and
   Opportunities
   TBA

5. Wrap-up
   Judith Currier, MD, MSc
SITE STAFF TRAINING

SOURCE DOCUMENTATION COMMISSION

_Sunday, June 25, 2017, 10:15 a.m. – 11:00 a.m._

**Facilitator:** Kathy Watson, RN
Ohio State University CRS

1. Introduction  
   Kathy Watson, RN

2. Source Documentation Commission  
   Shirley Ventresca, RN

3. Questions and Answers  
   All
SITE STAFF TRAINING

ADVERSE EVENT REPORTING/DIVISION OF AIDS ADVERSE EVENT REPORTING SYSTEM (DAERS)

*Sunday, June 25, 2017, 1:00 p.m. – 3:00 p.m.*

**Facilitator:** Sara Onesi, RN, CCRP  
University of Pittsburgh CRS

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Welcome and Introductions</td>
</tr>
</tbody>
</table>
| 2. | Division of AIDS Adverse Event Reporting System Training | Shirley Chacon, MD  
Imran Hasnuddin, MD |
| 3. | Questions and Answers | All |
SITE STAFF TRAINING

FIELD REPRESENTATIVE OVERVIEW

Sunday, June 25, 2017, 3:00 p.m. – 4:00 p.m.

Facilitator: Renee Weinman, BS, CCRP
University of Pittsburgh CRS

1. Welcome and Introductions Renee Weinman
2. Field Representative Overview Kathy Watson, RN
3. Questions and Answers All
SITE STAFF TRAINING
COMMUNITY/STAFF INTERACTIVE - INTERSECTIONALITY

Sunday, June 25, 2017, 4:00 p.m. – 6:00 p.m.

**Facilitator:** Renee Weinman, RN, CCRP
University of Pittsburgh CRS

1. Welcome and Introductions
   Renee Weinman, RN, CCRP

2. Intersectionality Discussion
   Jonatan Gioia, MD
   Community Members
   CRS Staff

3. Questions and Answers
   All
SITE STAFF TRAINING
STANDARD OPERATING PROCEDURE WORKSHOP

Monday, June 26, 2017, 8:30 a.m. – 10:30 a.m.

Facilitator: Suzanne Fiorillo, MSPH
University of Colorado Hospital CRS

1. Welcome and Introductions Suzanne Fiorillo, MSPH
2. Standard Operating Procedure Development Lysa Triantafillou
3. Questions and Answers All
SITE STAFF TRAINING

PROTOCOL FUNDING AND COSTING

Monday, June 26, 2017, 10:30 a.m. – 12:00 p.m.

Facilitator:  Carl Bruton, BBA
             Ohio State University CRS

1. Welcome and Introductions  Carl Bruton, BBA
2. Protocol Funding and Costing  Aisha Zaidi, MS
                               Ellyn Sherman
3. Questions and Answers  All
SITE STAFF TRAINING

MONITORING: UNDERSTANDING CODES AND RELATED FINDINGS & ELECTRONIC SOURCE RECORD

*Monday, June 26, 2017, 1:00 p.m. – 3:00 p.m.*

**Facilitator:** Carl Bruton, BBA
Ohio State University CRS

1. Welcome and Introductions
   Carl Bruton, BBA

2. Monitoring: Understanding Codes and Related findings & Electronic Source Record
   Pharmaceutical Product Development

3. Questions and Answers
   All
PROTOCOL-SPECIFIC TRAININGS

A5349/TBTC STUDY 31 (RIFAPENTINE-CONTAINING TUBERCULOSIS TREATMENT SHORTENING REGIMENS) PROTOCOL-SPECIFIC TRAINING SESSIONS

**ACTG Co-Chairs:** Sue Swindells, MBBS
University of Nebraska Medical Center/
University of Colorado Hospitals CRS

Wadzanai Samaneka, MBChb, MSc
Parirenyatwa CRS

**TBTC Co-Chairs:** Susan Dorman, MD
John Hopkins University

Payam Nahid, MD, MPH
University of California, San Francisco

1. **A5349/TBTC Study 31 Laboratory Focus Training**
   Tuesday, June 27, 2017, 7:00 a.m. – 8:00 a.m.
   Nicole Brown, PhD
   Ann Purfield, PhD

2. **A5349/TBTC Study 31 Team and Sites Session**
   Tuesday, June 27, 2017, 1:30 p.m. – 3:30 p.m.
   Susan Dorman, MD
   Sue Swindells, MD
   Payam Nahid, MD
   Ekaterina Kurbatova, MD

3. **A5349/TBTC Study 31 Drop-in Room**
   Tuesday, June 27, 2017, 3:30 p.m. – 4:30 p.m.
   Susan Dorman, MD
   Payam Nahid, MD
   Ekaterina Kurbatova, MD
   Andrew Vernon, MD

4. **A5349/TBTC Study 31 Tuberculosis Lab MGIT Testing Algorithm Interactive**
   Tuesday, June 27, 2017, 4:00 p.m. – 5:30 p.m.
   Nicole Brown, PhD
   Anne Purfield, PhD

5. **A5349/TBTC Study 31 Data Management Session**
   Wednesday, June 28, 2017, 1:30 p.m. – 3:30 p.m.
   Erin Sizemore, MPH
PROTOCOL-SPECIFIC TRAINING

A5354/EARLIER (EARLY ART IN ACUTE HIV) TEAM AND SITES INTERACTIVE TRAINING SESSION

Tuesday, June 27, 2017, 5:30 p.m. – 6:30 p.m.

Co-Chairs: Jintanat Ananworanich, MD, PhD
Kenya Medical Research Institute/Walter Reed Project Clinical Research Center CRS

Eric Daar, MD
Harbor University of California Los Angeles Center CRS

Co-Vice Chairs: Trevor Crowell, MD, PhD
Kenya Medical Research Institute/Walter Reed Project Clinical Research Center CRS

Javier Lama, MD, MPH
IMPACTA Peru CTU

1. Welcome and Introductions
Eric Daar, MD

2. Review of Acute HIV-1 Infection Eligibility Scenarios
Trevor Crowell, MD, PhD
Eric Daar, MD
Javier Lama, MD, MPH

3. Discussion of Fiebig Staging Evolution
Trevor Crowell, MD, PhD
Robert Coombs, MD
Eric Daar, MD
Javier Lama, MD, MPH

a. Estimated Fiebig Groups and Actual Fiebig Stage Results

b. Management of Participants with Fiebig Stage VI from Centralized Testing

4. Blood Volume Considerations
Eric Daar, MD
Trevor Crowell, MD, PhD
LuAnn Borowski, MSc

5. Site Questions and Comments
All Sites

6. Concluding Remarks
Trevor Crowell, MD, PhD
Eric Daar, MD
Javier Lama, MD, MPH
PROTOCOL-SPECIFIC TRAINING

A5360 (MINMON STUDY) PROTOCOL TRAINING

Tuesday, June 27, 2017, 4:00 p.m. – 5:30 p.m.

Chair: Sunil Solomon, MBBS, PhD, MPH
Johns Hopkins University CRS

Co-Vice Chairs: Sandra Wagner Cardoso, MD, PhD
Instituto de Pesquisa Clinica Evandro Chagas CRS

Mark Sulkowski, MD
Johns Hopkins University CRS

4:00 Self-hair Sample Collection
Monica Gandhi, MD, MPH

4:30 Development of Site-specific Contraindicated Medication Lists
Sunil Solomon, MBBS, PhD, MPH
Sandra Wagner Cardoso, MD, PhD
Mark Sulkowski, MD
Anchalee Avihingsanon, MD, PhD

5:00 Remote Contact eCRFS
Christine Scello, MA
Laura Weichmann, MPH
PROTOCOL-SPECIFIC TRAINING

NEUROPSYCHOLOGICAL BATTERY, NEUROLOGICAL EXAMINATION, AND LUMBAR PUNCTURE TRAINING FOR A5324 (ART INTENSIFICATION FOR HAND)

Wednesday, June 28, 2017, 4:00 p.m. – 6:00 p.m.

Co-Chairs: Kevin Robertson, PhD
Chapel Hill CRS

Serena Spudich, MD
Weill Cornell Chelsea CRS

Vice Chair: Scott Letendre, MD
University of California, San Diego AntiViral Research Center CRS

1. Welcome and Overview
   Kevin Robertson, PhD

2. Neurological Examination
   Serena Spudich, MD

3. Lumbar Puncture
   Serena Spudich, MD

4. Neuropsychological Examination
   Kevin Robertson, PhD
   a. Video
   b. Hands-on activity
A5264 (LIMITED KS STUDY) TEAM AND SITES SESSION

Tuesday, June 27, 2017, 12:30 p.m. – 1:30 p.m.

Chairs: Thomas Campbell, MD
University of Colorado Hospital CRS

Mina Hosseinipour, MD, MPH
University of North Carolina Global HIV Prevention and Treatment CTU

1. Welcome and Introductions
   Thomas Campbell, MD
   Mina Hosseinipour, MD, MPH

2. Primary Results Presentation
   Mina Hosseinipour, MD, MPH

3. Review of Secondary Manuscripts
   Mina Hosseinipour, MD, MPH

4. Site Questions and Comments
   All Sites

5. Manuscript Writing Team Assignments
   Mina Hosseinipour, MD, MPH
   Thomas Campbell, MD
A5300B/I2003B/PHOENIX SITE TRAINING

Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)

Monday, June 26, 2017, 8:00 a.m. – 12:00 p.m.

Co-Chairs: Gavin Churchyard, MBBCh, MMed, FRCP, FCP(SA), PhD (ACTG)
The Aurum Institute

Amita Gupta, MD, MHS (IMPAACT)
Johns Hopkins Center for Clinical Global Health Education

Anneke Hesseling, MD, PhD (IMPAACT)
Stellenbosch University

Sue Swindells, MBBS (ACTG)
University of Nebraska Medical Center

1. Welcome and Introductions
   Sue Swindells

2. Lessons Learned from the A5300/I2003/PHOENIx Feasibility Study, Including the One Year Follow-Up
   Amita Gupta

3. A5300B/I2003B/PHOENIx Overview
   Gavin Churchyard

4. Site Preparations for Lab Assays
   Patty Anthony, CLS
   Anita Gillis

5. TB Microbiological Considerations
   Anne-Marie Demers, MD

6. Review of Delamanid Literature and Adverse Events Relevant to PHOENIx, PK in Adults and Children
   Jeff Hafkin, MD, MSCE

7. Adherence Overview and Use of Electronic Drug Monitoring Device
   Jessica Haberer, MD, MS

8. Pediatric TB Contact Evaluation and Diagnosis
   Nicole Salazar-Austin, MD
A5345 (HIV REBOUND AND CONTROL BIOMARKERS)/A5347s (SAMPLING SUBSTUDY OF A5345) TEAM AND SITES SESSION
*GCAB/CSS Members Welcome*

Wednesday, June 28, 2017, 4:00 p.m. – 5:00 p.m.

Co-Chairs: Jonathan Li, MD
Brigham and Women's Hospital Therapeutics CRS

Davey Smith, MD
University of California, San Diego AntiViral Research Center CRS

Bernard Macatangay, MD
University of Pittsburgh CRS

Co-Vice Chairs: Steven Deeks, MD
University of California, San Francisco HIV/AIDS CRS

Rajesh Gandhi, MD
Massachusetts General Hospital (MGH) CRS

1. Welcome  
   Jonathan Li, MD

2. A5345 Overview  
   Jonathan Li, MD

3. A5347s Overview  
   Bernard Macatangay, MD

4. Recruitment Discussion  
   Protocol Team Members and Staff

5. Questions and Answers  
   All
REPRIEVE (A5332) SESSION:
NATIONAL HEART, LUNG, AND BLOOD (NHLBI) INITIATIVES
AND REPRIEVE TRIAL UPDATES

Wednesday, June 28, 2017, 12:30 p.m. – 1:30 p.m.

Principal Investigators: Steven Grinspoon, MD
Harvard Medical School/Massachusetts General Hospital

Pamela Douglas, MD
Duke Clinical Research Center

Udo Hoffmann, MD, MPH
Massachusetts General Hospital

Heather Ribaudo, PhD
ACTG Statistical and Data Analysis Center

Co-Investigators: Turner Overton, MD
Alabama CRS

Carl Fichtenbaum, MD
Cincinnati CRS

Judith Aberg, MD
Mt. Sinai Beth Israel CRS

Markella Zanni, MD
Massachusetts General Hospital CRS

12:40 Welcome
Turner Overton, MD

12:45 Progress to Date/ REPRIEVE Updates
Steven Grinspoon, MD

1:00 NHLBI Initiatives
David Goff, MD

1:15 A5361s: PREPARE Substudy of REPRIEVE (A5332)
Kristine Erlandson, MD

1:20 Question and Answer
Team